Life Sciences

Marlborough-based Boston Scientific Corp. (NYSE: BSX) saw revenue climb 6 percent over 2013 in the third quarter, driven largely by sales of its cardiovascular products, according to an earnings statement released Tuesday. Net sales for the company totaled $1.8 billion in the quarter ended Sept. 30, up from $1.7 billion a year earlier. Earnings per share increased to 3 cents, compared with less than a penny per share a year earlier, on net income of $43 million. That's a turnaround from a net loss of $5 million in the third quarter of 2013.

Milford-based laboratory instrument manufacturer Waters Corp. reported an 8-percent jump in sales for the third quarter and a 15-percent rise in net income as the company cited broad-based demand from pharmaceutical companies for its products.

An Ashland company has created a spinoff to commercialize medical devices that use nanotechnology to treat patients with heart and kidney disease.

Dr. Oliver Rando, a professor of biochemistry and molecular pharmacology at UMass Medical School, has received one of 10 Pioneer Awards granted to researchers by the National Institutes of Health (NIH), the medical school announced.

The medical technology industry, a growing sector of the Massachusetts economy, is expected to grow at a 5-percent annual rate through 2020, according to a forecast from a market research firm.

The new $80-million Quest Diagnostics laboratory in Marlborough will be a hub of innovation, as well as the center for medical testing services for patients throughout New England, Quest CEO Steve Rusckowski told guests gathered to celebrate the opening of the Forest Street facility Thursday morning.

Marlborough-based Sunovion Pharmaceuticals said it has agreed to sell rights to its drug Xopenex Inhalation Solution (IS), used in the treatment of obstructive airway disease such as asthma.

Harvard Bioscience Inc. (NASDAQ:HBIO), a Holliston-based manufacturer of life sciences equipment, has acquired two companies for a total of $11 million, the company announced Wednesday. The deals are expected to boost the company's electrophysiology business.

Advanced Cell Technology has completed the initial phase of its clinical-trial treatment for Stargardt's macular degeneration (SMD), a genetic eye disorder that causes progressive vision loss, the Marlborough company announced.

Marlborough-based Boston Scientific Corp. (NYSE: BSX) has initiated a clinical trial to evaluate the safety and effectiveness of the Lotus Valve System, designed to treat patients with severe aortic stenosis, a condition that prevents the aorta from opening fully.